Tanios S. Bekaii-Saab, MD, FACP introduces the metastatic colorectal cancer (mCRC) treatment landscape and the emphasizes importance of biomarker testing in patients with mCRC.
Back
Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and Beyond
Tanios S. Bekaii-Saab, MD, FACP describes the current colorectal cancer (CRC) treatment landscape, shares relevant updates from the American Society for Clinical Oncology’s Gastrointestinal Cancers Symposium 2023, and discusses his hopes for the future of the field.
Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and Beyond
Episodes
All
All
An expert in gastrointestinal cancers reviews outcomes from the MOUNTAINEER clinical trial, focusing on concordance analysis data for HER2 testing as well as the efficacy of tucatinib and trastuzumab.
Clinical insights regarding the design, patient population, and overall aims of the ongoing phase 3 clinical trial MOUNTAINEER-03.
Discussion centered around emerging treatment options for patients with HER2+ mCRC, including trastuzumab deruxtucan.
Dr Tanios S. Bekaii-Saab closes the discussion with key unmet needs in the mCRC treatment landscape.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5